ArticlePloS one2026
Prevalence of undiagnosed hypertension and risk assessment using a validated survey in community-based screening in Amman, Jordan.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe rising incidence of hypertension in Jordan has contributed to high rates of associated morbidity/mortality and increased societal costs. Hypertension affects approximately 30% of Jordan's adult population. This study assessed the prevalence of undiagnosed hypertension through blood pressure measurement and evaluated future hypertension risk using a validated survey in a community setting. The survey instrument incorporates demographic and clinical factors to predict the likelihood of hypertension development within a nine-year timeframe.
methodsWe conducted a cross-sectional local community screening in Amman, Jordan (Sept 2022-Sept 2023). Trained university pharmacy students had measured blood pressure and distributed a validated 9-risk predictors questionnaire to adults without diagnosed hypertension during a single visit. Participants were categorized using American Heart Association criteria.
resultsAmong 932 adult participants of the study, approximately 57% were female, 34% were overweight, 16% were obese, and 5.3% were extremely obese. Risk factors included current smoking (38%), diabetes mellitus comorbidity (8%), family history of hypertension (61%), and insufficient exercise (62%). Systolic readings were classified as elevated (45%), stage 1 (15%), or stage 2 (5.5%). Diastolic readings had stage 1 (42%) or stage 2 (7.6%). Participants with risk scores ≥17 (n = 39) were those who had current hypertension (BP ≥ 140/90 mmHg). Those were classified as high-risk based on established cutoffs.
conclusionOur community screening revealed a high prevalence of undiagnosed hypertension (20.6%) and identified a substantial proportion at high risk for future hypertension. The risk assessment tool showed good screening ability to reveal the participants' hypertension status, supporting its utility for risk stratification in resource-limited settings. Moreover, our validated risk tool effectively classified between those with and without current hypertension and identified individuals needing intensive preventive interventions. This dual approach of BP measurement and risk assessment may guide targeted screening intervals and preventive interventions in Jordan and similar settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.